Production (Stage)
XORTX Therapeutics Inc.
XRTX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.36% | -3.43% | 0.40% | 1.25% | 1.66% |
| Depreciation & Amortization | 5.71% | -16.18% | -16.32% | -26.13% | -13.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.44% | -47.20% | -57.83% | -56.01% | -53.11% |
| Operating Income | 28.44% | 47.20% | 57.83% | 56.01% | 53.11% |
| Income Before Tax | 70.31% | -53.53% | 90.09% | 79.69% | 51.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 70.31% | -53.53% | 90.09% | 79.69% | 51.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.31% | -53.53% | 90.09% | 79.69% | 51.15% |
| EBIT | 28.44% | 47.20% | 57.83% | 56.01% | 53.11% |
| EBITDA | 19.08% | 40.29% | 58.54% | 56.66% | 53.60% |
| EPS Basic | 79.15% | -21.23% | 99.12% | 88.21% | 67.00% |
| Normalized Basic EPS | 79.15% | -21.24% | 99.11% | 88.21% | 66.99% |
| EPS Diluted | 79.02% | -20.48% | 99.12% | 88.16% | 66.86% |
| Normalized Diluted EPS | 79.15% | -21.24% | 99.11% | 88.21% | 66.99% |
| Average Basic Shares Outstanding | 52.15% | 45.25% | 36.17% | 34.04% | 31.54% |
| Average Diluted Shares Outstanding | 52.15% | 45.25% | 36.17% | 34.04% | 31.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |